Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 12, Issue 2 (2023)

Pathogens isolated from clinical cases of lower urinary tract disorders in dogs and their antibiogram

Author(s):
Lathamani VS, Ramesh PT and Veena MP
Abstract:
The main objective of this study was to isolate the pathogens from lower urinary disorders of infectious origin and to study the antibiogram pattern of those pathogens among the dogs that were presented to Veterinary College, Bangalore during the period from March 2018 to September 2019. A total of 9780 dogs were presented to the Veterinary hospital during study period, out of these 276 were suspected for having lower urinary tract disorder based on history and clinical symptoms and were taken for detailed study. Among 276 dogs, 226 were diagnosed with lower urinary tract disorders of infectious origin viz., bacterial urinary tract infection (BUTI) of lower urinary tract (cystitis and/ urethritis), urolithiasis, transitional cell carcinoma (TCC) of urinary bladder with concurrent infections and prostate diseases. The most common bacterial pathogens isolated from urine sample were E. coli followed by Staphylococcus spp., Proteus spp., Pseudomonas spp., and Streptococci spp.
Antibacterial sensitivity pattern of E. coli isolates showed highest sensitivity for ceftriaxone-tazobactam (89.47%), Staphylococcus spp. showed highest sensitivity to enrofloxacin (91.49%). Higher antibacterial sensitivity pattern of Proteus spp. was showed towards amoxycillin with clavulanic acid (94.12%), Pseudomonas spp. isolates were sensitive to enrofloxacinin (100%) and Streptococcus spp. showed 100% sensitivity towards amoxicillin+clavulanic acid and ceftriaxone+tazobactam followed by doxycycline (83.33%), cefixime (66.66%).
Pages: 3385-3389  |  386 Views  234 Downloads


The Pharma Innovation Journal
How to cite this article:
Lathamani VS, Ramesh PT, Veena MP. Pathogens isolated from clinical cases of lower urinary tract disorders in dogs and their antibiogram. Pharma Innovation 2023;12(2):3385-3389.

Call for book chapter